Trials / Conditions / Toxic Epidermal Necrolysis

Toxic Epidermal Necrolysis

11 registered clinical trials studyying Toxic Epidermal Necrolysis — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis NCT03585946	Massachusetts General Hospital	—
Not Yet Recruiting	New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. NCT07110662	Hospices Civils de Lyon	Phase 1 / Phase 2
Recruiting	LYell SYndrome MEsenchymal Stromal Cells Treatment NCT04711200	Assistance Publique - Hôpitaux de Paris	Phase 1 / Phase 2
Recruiting	Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment NCT06119490	Peng Zhang	EARLY_Phase 1
Completed	Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN NCT06474078	Chang Gung Memorial Hospital	N/A
Withdrawn	Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs NCT02795143	Massachusetts General Hospital	N/A
Withdrawn	Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis NCT02319616	University of California, Davis	Phase 1 / Phase 2
Unknown	Severe Cutaneous Adverse Reactions in Thailand NCT02574988	Chulalongkorn University	—
Completed	Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unres NCT01696500	Nihon Pharmaceutical Co., Ltd	Phase 3
Terminated	Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis NCT02037347	Brett King	Phase 1 / Phase 2
Withdrawn	Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) NCT00372723	Loyola University	Phase 2